Regeneron Pharmaceuticals, Inc.
REGN
$589.48
-$8.68-1.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.65B | 13.61B | 13.69B | 13.30B | 12.92B |
| Total Other Revenue | 559.40M | 480.00M | 515.00M | 548.10M | 572.20M |
| Total Revenue | 14.21B | 14.09B | 14.20B | 13.85B | 13.49B |
| Cost of Revenue | 7.48B | 7.21B | 7.10B | 6.82B | 6.57B |
| Gross Profit | 6.73B | 6.87B | 7.10B | 7.03B | 6.92B |
| SG&A Expenses | 2.77B | 2.90B | 2.95B | 2.90B | 2.83B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -500.00K | -1.00M |
| Total Operating Expenses | 10.26B | 10.11B | 10.06B | 9.72B | 9.39B |
| Operating Income | 3.96B | 3.98B | 4.15B | 4.13B | 4.10B |
| Income Before Tax | 4.87B | 4.98B | 4.78B | 4.97B | 4.59B |
| Income Tax Expenses | 416.20M | 484.90M | 367.30M | 314.90M | 265.50M |
| Earnings from Continuing Operations | 4.46K | 4.50K | 4.41K | 4.65K | 4.32K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.46B | 4.50B | 4.41B | 4.65B | 4.32B |
| EBIT | 3.96B | 3.98B | 4.15B | 4.13B | 4.10B |
| EBITDA | 4.47B | 4.47B | 4.63B | 4.60B | 4.55B |
| EPS Basic | 41.75 | 41.76 | 40.88 | 43.23 | 40.31 |
| Normalized Basic EPS | 27.36 | 27.12 | 27.90 | 27.49 | 27.14 |
| EPS Diluted | 39.69 | 39.29 | 38.29 | 40.41 | 37.76 |
| Normalized Diluted EPS | 25.98 | 25.52 | 26.14 | 25.69 | 25.43 |
| Average Basic Shares Outstanding | 427.50M | 430.50M | 431.60M | 430.60M | 428.80M |
| Average Diluted Shares Outstanding | 449.80M | 456.60M | 460.50M | 460.50M | 457.70M |
| Dividend Per Share | 1.76 | 0.88 | -- | -- | -- |
| Payout Ratio | 4.18% | 2.08% | -- | -- | -- |